Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Novel transcript, antisense to Ubiquitin-specific peptidase 54 (ENSG00000300743)
- Target
- ENSG00000300743
- Molecular classification
- Long non-coding RNA (lncRNA), Antisense transcript
01
Overview
This molecule is a novel antisense transcript that originates from the DNA strand opposite the USP54 gene locus. Such antisense transcripts are a class of long non-coding RNAs (lncRNAs) that can modulate the expression of their sense gene partners through several regulatory mechanisms including chromatin modification, transcript stability, and alterations in processing dynamics[1][2][3]. In general, antisense transcription is widespread in the human genome and may influence gene expression and stability, often with context-dependent impact. However, this particular transcript is not well-characterized, and there is no evidence it encodes a protein or has a role as a therapeutic target.
- Other names
- NAT to USP54Natural antisense transcript to USP54LncRNA antisense to USP54 (if functionally characterized as a long non-coding RNA, but this is not confirmed)
02
Mechanism of action
None
03
Biological functions
Modulation of sense gene expressionRegulation of chromatin stateRegulation of transcript stability and processingPossibly involved in mRNA splicingSpecific biological functions for the USP54 antisense transcript are unknown.
04
Disease associations
Cancer (some NATs involved in oncogenic or tumor-suppressor pathways)Neurodevelopmental and neurodegenerative diseases (depending on gene context)No direct evidence for disease involvement of the USP54 antisense transcript.
Beyond the preview
Go deeper on Novel transcript, antisense to Ubiquitin-specific peptidase 54 (ENSG00000300743).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Novel transcript, antisense to Ubiquitin-specific peptidase 54 (ENSG00000300743).